Rhumbline Advisers Purchases 5,854 Shares of Annexon, Inc. (NASDAQ:ANNX)

Rhumbline Advisers increased its holdings in Annexon, Inc. (NASDAQ:ANNX) by 4.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 141,852 shares of the company’s stock after acquiring an additional 5,854 shares during the quarter. Rhumbline Advisers owned about 0.13% of Annexon worth $728,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of the business. Parkman Healthcare Partners LLC boosted its holdings in Annexon by 0.5% in the third quarter. Parkman Healthcare Partners LLC now owns 328,613 shares of the company’s stock worth $1,945,000 after acquiring an additional 1,768 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in Annexon by 1.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 159,586 shares of the company’s stock worth $945,000 after purchasing an additional 2,450 shares in the last quarter. GSA Capital Partners LLP grew its position in Annexon by 10.7% during the 3rd quarter. GSA Capital Partners LLP now owns 34,581 shares of the company’s stock valued at $205,000 after purchasing an additional 3,355 shares during the last quarter. MetLife Investment Management LLC increased its stake in Annexon by 11.8% during the 3rd quarter. MetLife Investment Management LLC now owns 55,212 shares of the company’s stock valued at $327,000 after purchasing an additional 5,814 shares in the last quarter. Finally, Creative Planning increased its stake in Annexon by 29.5% during the 3rd quarter. Creative Planning now owns 34,779 shares of the company’s stock valued at $206,000 after purchasing an additional 7,914 shares in the last quarter.

Annexon Stock Up 3.0 %

Shares of ANNX stock opened at $2.76 on Friday. The company’s fifty day simple moving average is $3.75 and its two-hundred day simple moving average is $5.34. Annexon, Inc. has a 52 week low of $2.30 and a 52 week high of $8.40. The stock has a market cap of $294.20 million, a P/E ratio of -2.63 and a beta of 1.14.

Annexon (NASDAQ:ANNX) last posted its earnings results on Monday, March 3rd. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05). On average, analysts anticipate that Annexon, Inc. will post -0.96 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on ANNX. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Annexon in a research report on Tuesday, December 17th. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 price target on shares of Annexon in a report on Tuesday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a research report on Friday, November 15th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Annexon currently has an average rating of “Buy” and an average price target of $15.80.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.